Aberrant upregulation of 14-3-3o{horn} expression serves as an inferior prognostic biomarker for gastric cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Zhou, Wei Hua ^a,b   Tang, Fang ^a   Xu, Jie ^b   Wu, Xing ^a,b   Feng, Zhi Ying ^a   Li, Hai Gang ^a   Lin, Dong Jun ^a   Shao, Chun Kui ^a   Liu, Quentin ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

STRATIFIN; EXONUCLEASE; PROTEIN 14 3 3; SFN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL TIME; UPREGULATION; BIOSYNTHESIS; CHEMISTRY; DISEASE COURSE; DISEASE FREE SURVIVAL; FOLLOW UP; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; STOMACH MUCOSA; STOMACH TUMOR; TISSUE MICROARRAY; WESTERN BLOTTING;

14-3-3 PROTEINS; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EXONUCLEASES; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; ROC CURVE; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 80053174517     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-397     Document Type: Article

References (34)

1. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Annals of surgery 2005, 241(1):27-39. 1356843, 15621988.
2. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgraduate medical journal 2005, 81(957):419-424. 10.1136/pgmj.2004.029330, 1743301, 15998815.
3. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006, 12(1):17-20.
4. Zheng L, Wang L, Ajani J, Xie K. Molecular basis of gastric cancer development and progression. Gastric Cancer 2004, 7(2):61-77.
5. Zhang XW, Sheng YP, Li Q, Qin W, Lu YW, Cheng YF, Liu BY, Zhang FC, Li J, Dimri GP, et al. BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Molecular cancer 2010, 9:40. 10.1186/1476-4598-9-40, 2842237, 20170541.
6. de Maat MF, van de Velde CJ, Umetani N, de Heer P, Putter H, van Hoesel AQ, Meijer GA, van Grieken NC, Kuppen PJ, Bilchik AJ, et al. Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol 2007, 25(31):4887-4894. 10.1200/JCO.2006.09.8921, 17971584.
7. Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, Sugihara K. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 2008, 14(23):7843-7849. 10.1158/1078-0432.CCR-08-1064, 19047113.
8. Chatterjee D, Sabo E, Tavares R, Resnick MB. Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res 2008, 14(10):2994-3001. 10.1158/1078-0432.CCR-07-4496, 18483365.
9. Zhao ZS, Wang YY, Chu YQ, Ye ZY, Tao HQ. SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2010, 16(1):260-268. 10.1158/1078-0432.CCR-09-1247, 20028745.
10. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer treatment reviews 2010, 36(Suppl 3):S11-15.
11. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697. 10.1016/S0140-6736(10)61121-X, 20728210.
12. Mhawech P. 14-3-3 proteins--an update. Cell research 2005, 15(4):228-236. 10.1038/sj.cr.7290291, 15857577.
13. Pozuelo Rubio M, Geraghty KM, Wong BH, Wood NT, Campbell DG, Morrice N, Mackintosh C. 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. The Biochemical journal 2004, 379(Pt 2):395-408. 1224091, 14744259.
14. Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annual review of pharmacology and toxicology 2000, 40:617-647. 10.1146/annurev.pharmtox.40.1.617, 10836149.
15. Mackintosh C. Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. The Biochemical journal 2004, 381(Pt 2):329-342. 1133837, 15167810.
16. Prasad GL, Valverius EM, McDuffie E, Cooper HL. Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 1992, 3(8):507-513.
17. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(11):6049-6054. 10.1073/pnas.100566997, 18556, 10811911.
18. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000, 19(46):5298-5302. 10.1038/sj.onc.1203898, 11077447.
19. Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M, Takahashi T. Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene 2002, 21(15):2418-2424. 10.1038/sj.onc.1205303, 11948426.
20. Lodygin D, Diebold J, Hermeking H. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression. Oncogene 2004, 23(56):9034-9041. 10.1038/sj.onc.1208004, 15489902.
21. Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, Nitta M, Okamura H, Inoue S, Sasano H, et al. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 2004, 10(8):2687-2693. 10.1158/1078-0432.CCR-03-0510, 15102672.
22. Yi B, Tan SX, Tang CE, Huang WG, Cheng AL, Li C, Zhang PF, Li MY, Li JL, Yi H, et al. Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. Journal of cellular biochemistry 2009, 106(5):858-866. 10.1002/jcb.22051, 19160382.
23. Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Steele D, Cossu A, Budroni M, Palmieri G, Lakhani SR. Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. The Journal of pathology 2004, 202(3):274-285. 10.1002/path.1530, 14991892.
24. Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY, Li F, Li JL, Li C, Yi H, et al. Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res 2008, 14(2):435-445. 10.1158/1078-0432.CCR-07-1215, 18223218.
25. Neupane D, Korc M. 14-3-3sigma Modulates pancreatic cancer cell survival and invasiveness. Clin Cancer Res 2008, 14(23):7614-7623. 10.1158/1078-0432.CCR-08-1366, 3142357, 19047086.
26. Li Z, Dong Z, Myer D, Yip-Schneider M, Liu J, Cui P, Schmidt CM, Zhang JT. Role of 14-3-3sigma in poor prognosis and in radiation and drug resistance of human pancreatic cancers. BMC cancer 2010, 10:598. 10.1186/1471-2407-10-598, 2991307, 21040574.
27. Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, Margreiter R, Amberger A. 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 2005, 11(9):3274-3279. 10.1158/1078-0432.CCR-04-2207, 15867223.
28. Xie D, Sham JS, Zeng WF, Lin HL, Che LH, Wu HX, Wen JM, Fang Y, Hu L, Guan XY. Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. International journal of cancer 2003, 107(6):896-902.
29. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. Journal of clinical pathology 2007, 60(10):1112-1116. 10.1136/jcp.2006.044537, 2014838, 17182662.
30. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. The New England journal of medicine 2001, 345(10):725-730. 10.1056/NEJMoa010187, 11547741.
31. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999, 401(6753):616-620. 10.1038/44188, 10524633.
32. Wan XB, Fan XJ, Chen MY, Xiang J, Huang PY, Guo L, Wu XY, Xu J, Long ZJ, Zhao Y, et al. Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy 2010, 6(3):395-404. 10.4161/auto.6.3.11303, 20150769.
33. Zurita M, Lara PC, del Moral R, Torres B, Linares-Fernandez JL, Arrabal SR, Martinez-Galan J, Oliver FJ, Ruiz de Almodovar JM. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC cancer 2010, 10:217. 2889892, 20487521.
34. Ravi D, Chen Y, Karia B, Brown A, Gu TT, Li J, Carey MS, Hennessy BT, Bishop AJ. 14-3-3 sigma expression effects G2/M response to oxygen and correlates with ovarian cancer metastasis. PloS one 2011, 6(1):e15864. 10.1371/journal.pone.0015864, 3018427, 21249227.